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Abstract
Background: Human T-cell leukemia virus type 1 (HTLV-1) infection is associated with adult T-cell leukemia/lymphoma
(ATLL), a lymphoproliferative malignancy with a dismal prognosis and limited therapeutic options. Recent evidence
shows that HTLV-1-transformed cells present defects in both DNA replication and DNA repair, suggesting that these
cells might be particularly sensitive to treatment with a small helicase inhibitor. Because the “Werner syndrome
ATP-dependent helicase” encoded by the WRN gene plays important roles in both cellular proliferation and DNA
repair, we hypothesized that inhibition of WRN activity could be used as a new strategy to target ATLL cells.
Methods: Our analysis demonstrates an apoptotic effect induced by the WRN helicase inhibitor in HTLV-1-transformed
cells in vitro and ATL-derived cell lines. Inhibition of cellular proliferation and induction of apoptosis were
demonstrated with cell cycle analysis, XTT proliferation assay, clonogenic assay, annexin V staining, and
measurement of mitochondrial transmembrane potential.
Results: Targeted inhibition of the WRN helicase induced cell cycle arrest and apoptosis in HTLV-1-transformed
leukemia cells. Treatment with NSC 19630 (WRN inhibitor) induces S-phase cell cycle arrest, disruption of the
mitochondrial membrane potential, and decreased expression of anti-apoptotic factor Bcl-2. These events were
associated with activation of caspase-3-dependent apoptosis in ATL cells. We identified some ATL cells, ATL-55T
and LMY1, less sensitive to NSC 19630 but sensitive to another WRN inhibitor, NSC 617145.
Conclusions: WRN is essential for survival of ATL cells. Our studies suggest that targeting the WRN helicase with
small inhibitors is a novel promising strategy to target HTLV-1-transformed ATL cells.
Keywords: Human T-cell leukemia virus type 1 (HTLV-1), Adult T-cell leukemia/lymphoma (ATLL), WRN helicase,
Cycle arrest, Apoptosis
Background
Human T-cell leukemia virus type 1 (HTLV-1) is a retro-
virus that infects over 20 million people worldwide and is
the etiological agent of adult T-cell leukemia/lymphoma
(ATLL) [1, 2], an aggressive malignancy of mature acti-
vated T cells. HTLV-1 is associated with transformation of
T lymphocytes and the development of ATLL in approxi-
mately 1–4% of infected individuals following a long
latency period [3]. The diversity in clinical presentation
and response to therapy of ATLL patients leads to classifi-
cation into four subtypes: acute, lymphoma, chronic, and
smoldering, based on organ involvement, lactate dehydro-
genase (LDH), and calcium values [4]. Patients with
aggressive forms of ATLL, the acute and lymphoma types,
display a poor prognosis, with a median survival of
approximately 1 year [5], and resistance to aggressive
combined chemotherapy. Several clinical trials show that
first-generation polychemotherapy containing doxorubicin
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(CHOP) has a limited effect on ATLL patients [6], while
other approaches have yielded limited long-term benefits
to ATL patients with acute or lymphoma type. In general,
HTLV-1-associated disease has a poor clinical outcome,
with 4-year survival rates for acute and lymphoma sub-
types at 5 and 5.7%, respectively [7, 8]. The mechanism by
which HTLV-1 induces T-cell transformation remains un-
clear; however, the viral Tax protein plays an essential role
in the immortalization of human T lymphocytes [9, 10].
HTLV-1 activates an oncogenic signaling pathway, such as
NF-kB and Jak/STAT [11, 12], and affects the expression
of cellular miRNAs [13–16]. In addition, HTLV-1 infec-
tion leads to inactivation of several tumor suppressors and
epigenetic regulators, including p16ink, Rb, p53 and
p21waf, TET2, and MLL3 [17, 18]. HTLV-1-transformed
cells are characterized by an increase of phospho-ATM
and accumulation of -H2AX, suggesting a high level of
DNA damage in those cells [19, 20]. Consistently, Tax was
found to induce DNA double-strand breaks (DDSB), in an
NF-kB-dependent manner, and is responsible for alter-
ation of DNA repair machinery. Tax induces DDSB during
the S-phase of the cell cycle, which are normally repaired
through error-free Homologous Recombination repair
(HR); however, in HTLV-1-transformed cells, the DNA
damage is preferentially repaired by the error-prone non-
homologous end joining (NHEJ) pathway [21, 22]. Overall,
this evidence shows that Tax, by inducing DDSB and al-
tering the DNA repair, promotes genetic instability that
might be involved in the initiating events leading to
transformation. Furthermore, our recent study shows
that Tax-expressing cells display DNA replication is-
sues. The replication fork progression was found to be
slower and stalls more frequently in the presence of the
viral protein Tax [23], suggesting that these cells might
be sensitive to a DNA replication inhibitor.
Targeting DNA replication and repair machinery has
been proposed as a promising strategy to combat cancer
[24, 25]. Helicases are highly conserved enzymes that
unwind nucleic acid duplexes during DNA replication
and repair [26]. WRN mutations of the gene lead to
Werner syndrome, which is characterized by genetic in-
stability and hematological disease [27]. WRN helicases
are generally highly expressed in human leukemia [28]
and depletion of the gene results in mitotic catastrophe,
leading to cancer cell death [29]. Interestingly, evidence
shows that treatment with a WRN inhibitor (NSC
19630) significantly affects cellular proliferation of
leukemia cell lines [30]. WRN helicases are involved in
replication fork progression and participate in DNA
double-strand break repair through homologous repair
and the non-homologous end joining pathway [21]. De-
fects in DNA replication and DNA damage response in
the HTLV-1 context lead us to hypothesize that ATL
cells may be sensitive to treatment with a WRN
inhibitor. Here, we demonstrate that two small WRN in-
hibitors, NSC 19630 and NSC 617145, induce cell cycle
arrest and apoptosis in HTLV-1-transformed ATL cells.
Methods
Cell lines and reagent
HTLV-1-transformed cell lines (MT-4, C8166, C91PL,
and 1186.94 [31–33]) and ATL-derived cell lines, IL-2-
independent (ED-40515(−), TL-Om1, and ATL-25 [34,
35]), were maintained in RPMI-1640 media supple-
mented with penicillin, streptomycin, and 10% fetal bo-
vine serum (FBS). ATL-derived cell lines, IL-2-
dependent (LMY1, ATL-55T, ATL-43T SO4, KK1 [36–
42]), were maintained in RPMI-1640 media supple-
mented with IL-2 (50 U/mL), penicillin, streptomycin,
and 10% FBS. Peripheral blood mononuclear cells
(PBMCs) were isolated from healthy donors by using
Ficoll-Paque PLUS reagent (GE Healthcare Life Sci-
ences). PBMCs were maintained in RPMI-1640 media
supplemented with penicillin, streptomycin, and 20%
fetal bovine serum (FBS). WRN inhibitor NSC 19630
was purchased from EMD Millipore’s Calbiochem® and
NSC 617145 was purchased from Tocris Bioscience.
Cells were treated with different concentrations of WRN
inhibitors, and cells exposed to DMSO were used as a
control, as indicated in figure legends.
Cell cycle and proliferation assay
Cells were treated with the WRN inhibitor or DMSO as
a control. After 72 h, cells were collected and washed
twice with phosphate-buffered saline (PBS) and then
were fixed with 80% EtOH overnight at −20 °C. The fol-
lowing day, cells were washed twice with PBS, incubated
with RNase for 15 min at 37 °C, stained with 100 μg/mL
propidium iodide (PI) for 20 min, and analyzed on an
LSR II flow cytometer. Cell proliferation was measured
by microscopic cell count, Cell Proliferation Kit II
(XTT) (Roche), the XTT assay, according to the manu-
facturer’s instructions. Clonogenic assay was used to
study cell proliferation. Briefly, cells were washed twice
with PBS, fixed with cold Methanol (MeOH), and then
stained with crystal violet dye (0.5% MeOH) for 20 min
at room temperature.
Apoptosis assay and mitochondrial membrane potential
Inhibitor-treated and control cells were collected and
washed twice with PBS then stained with annexin
V/propidium iodide using the Alexa Fluor® 488 Annexin
V/Dead Cell Apoptosis Kit (Molecular Probes, Eugene,
OR) according to the manufacturer’s instructions. Mito-
chondrial membrane potential (ΔΨm) was measured
using the JC-1 Assay Kit (Invitrogen) according to the
manufacturer’s instructions.
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Western blotting
Cell lysates were separated on SDS-PAGE followed by
electroblotting to polyvinylidene difluoride membranes
and probed with cyclin D1 (M-20), cyclin E (C-19), cyc-
lin A (h432), cyclin B1 (H-20), actin (C-11), Bcl-2 (100),
Mcl-1 and caspase-3 (H-60), Tax mouse monoclonal
antibody (NIH AIDS Reagent Program, HTLV-I Tax Hy-
bridoma (168B17)), and appropriate secondary anti-
bodies purchased from Santa Cruz Biotechnology.
Immunofluorescence
Cells were centrifuged on slides at 800 rpm for 10 min.
Slides were fixed in 4% paraformaldehyde (PFA) for
15 min at room temperature and then permeabilized
with 0.5% Triton X-100 for 5 min on ice for 5 min.
Slides were blocked for 1 h in PBS with 0.5% gelatin
and 0.25% bovine serum albumin at room temperature.
For γ-H2AX and PCNA staining, slides were incubated
with anti-γ-H2AX (Ser139) antibody FITC conjugated
(Millipore Sigma) and PCNA antibody (DAKO, Agilent
Technologies) 1/200 in PBS for 2 h, washed three times
in PBS-0.2% gelatin for 10 min each time, and incu-
bated with the appropriate Alexa Fluor secondary anti-
body (Molecular Probes, Invitrogen) in PBS-0.2%
gelatin for 1 h at room temperature. Cells were washed
three times in PBS-0.2% gelatin for 10 min each time
and mounted by using DABCO mounting medium
(2.5% DABCO from Sigma, 200 mM Tris-HCl pH 8.6
and 90% glycerol). Fluorescent images were captured
with Nikon TE2000E epifluorescence microscope by
using the ×100 objective.
Statistical analysis
Experiments in Figs. 1, 2, 3, and 4 were performed mul-
tiple times in duplicate. Representative results were
shown in the final figures. P values were calculated by
using paired and two-tailed Student’s t test. P values are
reported in the figures and in the legends.
Results
NSC 19630 inhibitor induces S-phase cell cycle arrest
HTLV-1-derived cell lines and Tax-expressing cells dis-
play impaired DNA replication and repair, leading us to
hypothesize that these cells may be sensitive to treat-
ment with a small helicase inhibitor. In order to deter-
mine if the small inhibitor NSC 19630 affects cellular
proliferation, we exposed in vitro HTLV-1-transformed
cell lines (MT4, C8166, and C91PL) and patient-
derived ATLL cell lines (ED) to 3 μM of NSC 19630 or
DMSO control for 48 h. Cells were stained with propi-
dium iodide and DNA content was analyzed by FACS.
Consistent with the fact that WRN helicases are re-
quired to unwind double-stranded DNA to single-
stranded DNA during DNA replication [43], NSC
19630 treatment showed significant accumulation of
cells in the S-phase when compared with DMSO-
exposed cells (Fig. 1a, b). Previous studies demon-
strated that cells expressing a WRN-specific shRNA
displayed a reduction in cellular growth [44]. In fact,
WRN-depleted human fibroblasts show a marked delay
in completing the cell cycle by spending more time in
late S- and/or G2-phases of the cell cycle [45]. Consist-
ent with these observations, perturbation of cell cycle
progression was noted in HTLV-1-transformed and
ATL-derived cell lines (Fig. 1a, b). We included West-
ern blot of the Tax viral protein in cellular lysates de-
rived from MT4, C8166, C91PL, and ED (Fig. 1c). As
previously reported, our analysis identified ED as Tax-
negative and MT4, C8166, and C91PL as Tax-positive
cell lines. [23, 46]. Our analysis shows that NSC 19630
induces perturbation of cell cycle progression in both
Tax-negative and Tax-positive cells.
The expression of cell cycle progression regulatory
proteins was studied by Western blot in ED cells ex-
posed to 3 μM of WRN inhibitor for 72 h. We compared
the protein level of cyclins D1, E, A, and B1 in ED cells
treated with NSC 19630 versus DMSO-treated controls
(Fig. 1d). Cyclin E has a critical role in the control of the
G1- and S-phase transitions and in the initiation of
DNA replication [47]. Cyclin D1 levels vary during the
cell cycle, with an elevated level of cyclin D1 maintained
through G1-phase and required for the initiation of S-
phase, while levels are reduced to allow DNA synthesis
in S-phase [48]. However, increased levels of cyclin D1
are required to exit S-phase [48]. Similarly, cyclin A is
accumulated during S-phase and is degraded before
metaphase, while cyclin B1 is accumulated during the
G2/M-phase [49]. Treatment of ATL cells with the
WRN inhibitor NSC 19630 was associated with a de-
crease in the expression of cyclin D1, which may prevent
treated cells from S-phase exit and result in accumula-
tion of cells in S-phase (Fig. 1d). While there was no sig-
nificant change in cyclin A expression in NSC 19630-
treated cells, expression of cyclin E and cyclin B1 was
significantly reduced (Fig. 1d). We believe that a relative
decreased population in G2/M as a result of S-phase ar-
rest accounts for the decrease in cyclin B1.
In addition, we decided to include Western blot of
cyclins D1, E, A, and B1 in Tax-expressing cell line lys-
ate C8166 extracted from cells exposed to NSC 19630
compared to DMSO-treated controls. Our analysis
shows a reduction of cyclins E, D1, and B1 in Tax-
positive cells (Fig. 1d), suggesting that cells arrested dur-
ing the S-phase of the cell cycle.
Overall, our data revealed a profound alteration of the
cyclin expression profile in ATL cells exposed to the
WRN helicase inhibitor consistent with S-phase arrest.
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NSC 19630 inhibits cellular proliferation and induces
apoptosis in HTLV-1-transformed and patient-derived cells
Recent evidence shows that treatment with the WRN in-
hibitor NSC 19630 significantly affects the cellular growth
of different leukemia cell lines [30]. We next exposed
HTLV-1-transformed C91PL to increasing logarithmic
doses (0.2, 2, and 20 μM) or DMSO vehicle as a control
(Fig. 2a, b). Induction of cell death was measured by using
annexin V/PI staining. Apoptotic cells were scored as
annexin V+, necrotic dead cells as PI+, versus live cells,
which were annexin V-/PI-. We calculated the IC50 by
using logarithmic transformation and we compared it to
normal PBMCs isolated from healthy donors. Resting
PBMCs were treated with the same concentrations of
NSC 19630, 0.2, 2, and 20 μM, and induction of apoptosis
by using annexin V/PI staining was measured (Fig. 2b).
The IC50 in normal cells is higher compared to the
HTLV-1-transformed cell line, C91PL (9.28 ± 0.23 and
2.76 ± 0.29, respectively), showing that resting PBMCs iso-
lated from a healthy donor are less sensitive to the drug.
We expanded our analysis by testing the HTLV-1-
transformed (MT-4, C8166, C91PL, 1186.94) and ATL-
derived (ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1,
KK1, SO4, and KOB) cell lines with increasing doses of
NSC 19630, 0.2, 2, and 20 μM. Inhibition of cellular
growth was measured by using cell count and reported
in Fig. 2c. We calculated the IC50 for every cell line by
using logarithmic transformation, and the values are in-
dicated in Table 1. Interestingly, LMY1 and ATL-55T













































































Fig. 1 NSC 19630 inhibitor induces S-phase cell cycle arrest. a HTLV-1-transformed cell lines (C8166, C91PL, and MT4) and patient-derived cell lines
(ED) were treated with 3 μM of NSC 19630 and DMSO vehicle has a control. After 48 h, cells were stained with propidium iodide (PI) and DNA
content was analyzed by FACS to distinguish the different phases of the cell cycle (G0/G1, S, G2/M). The cell cycle analysis indicated an accumulation
of the percentage of cells in S-phase, suggesting that exposure to the helicase inhibitor induced accumulation of cells in the S-phase in HTLV-1-
transformed and ATL-derived cell lines. Experiment was performed multiple times in duplicate. Representative results are shown in the final figures.
b Graphic representation of the different percentages of G0/G1-, S-, and G2/M-phase cells treated with 3 μM of NSC 19630 compared to DMSO
control. c Western blots of Tax viral protein in ED, C8166, C91PL, and MT-4 cell lines. d Western blots of cyclin D1, cyclin A, cyclin E, and cyclin B1 in
ED and C8166 cells following 72 h of treatment with DMSO or 3 μM of NSC 19630. Actin was used to confirm equal loading
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cells were treated with 2 μM of WRN inhibitor (Fig. 3c).
Consistently, the IC50 was found to be higher in those
lines compared to the other cell lines tested in our study,
suggesting that LMY1 and ATL-55T are less sensitive to
the drug (Table 1). We included normal PBMCs isolated
from healthy donors in our analysis as a negative con-
trol. As expected, limited inhibition of proliferation was
noted in resting PBMCs treated with WRN inhibitor
(Fig. 2c) even at high concentrations.
Our analysis shows a dose-dependent inhibition of
cellular proliferation, suggesting that targeting WRN
activity represents a promising strategy to kill ATL
cells. These results were further confirmed by clono-
genic assay. Two patient-derived ATL cell lines with ad-
herent characteristics were exposed to 3 μM of NSC
19630 or DMSO for 72 h, washed, and then stained
with crystal violet. A significant reduction in the num-























































































































































Fig. 2 NSC 19630 inhibits cellular proliferation in patient-derived cells. a C91PL cells were exposed to increasing amounts of the WRN helicase
inhibitor NSC 19630 (0, 0.2, 2, and 20 μM). After 72 h, cells were stained with annexin V to determine the percentage of apoptosis. The figures
include the percentage of cells in the four quarters: Q1, Q2, Q3, and Q4. Q3 included the live cells that are annexin V and PI negative. Q4 included
early apoptotic cells, which are annexin V positive and PI negative. Q2 included cells in late apoptosis, which are both annexin V and PI positive.
Finally, Q1 included necrotic cells, which are PI positive and annexin V negative. A dose-dependent effect was noted. Experiment was performed
multiple times in duplicate. Representative results are shown in the final figures. b Normal resting PBMCs and C91PL were exposed to increasing
amounts of the WRN helicase inhibitor NSC 19630 (0, 0.2, 2, and 20 μM). After 72 h, cells were stained with annexin V and survival cells were
graphed. Experiment was performed in duplicate. P values were calculated comparing NSC-treated cells to DMSO control by using paired and
two-tailed Student’s t test and indicated in the figure. c HTLV-1-transformed (MT-4, C8166, C91PL, 1186.94) and ATL-derived (ED, TL, ATL-25,
ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) cell lines and normal resting PBMCs with increasing doses of NSC 19630 (0.2, 2, and 20 μM) show
inhibition of cellular growth as measured by using cell count. Experiment was performed multiple times in duplicate. Representative results are
shown in the final figures. d, e Patient-derived cell lines ATL-25 and LMY1 were treated with DMSO or 3 μM of NSC 19630 for 72 h and stained
with crystal violet to test the anti-proliferative property of the WRN helicase inhibitor. The results were confirmed with XTT assay and cell counts.
Experiment was performed multiple times in duplicate. Representative results were shown in the final figures. P values were calculated by using
paired and two-tailed Student’s t test and indicated in the figure
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significant changes were observed in LMY1, suggesting
that these cells are resistant to the WRN inhibitor
(Fig. 2e). To confirm these results, the anti-proliferative
effect of NSC 19630 was quantified by measuring cleav-
age of XTT to an orange formazan dye using an ELISA
reader at 450 nm and confirmed by microscopic cell
count. Consistently, our analysis identified LMY1 as
less sensitive to NSC 19630 (Fig. 2e). In contrast, ATL-
25 was sensitive to the anti-proliferative effect of the
WRN inhibitor (Fig. 2d).
The lack of effective therapeutic treatment for ATL
patients led us to investigate the cytotoxicity of NSC
19630. WRN inhibitor is reported to induce cell death
through accumulation of DNA double-strand breaks
(DDSB) [30]. A previous article published from our la-
boratory shows that Tax affects the DNA repair machin-
ery, more specifically by inhibiting Homologous
Recombination (HR) repair [21]. That evidence leads us
to speculate that NSC 19630 might induce cell death







Fig. 3 NSC 19630 induces apoptosis in HTLV-1-transformed and patient-derived cells. a ED and MT-4 cells were exposed to WRN helicase inhibitor
NSC 19630 (3 μM) or DMSO. After 72 h, cells were stained with annexin V. The figures include the percentage of cells in the four quarters: Q1, Q2,
Q3, and Q4. Q3 included the live cells that are annexin V and PI negative. Q4 included early apoptotic cells, which are annexin V positive and PI
negative. Q2 included cells in late apoptosis, which are both annexin V and PI positive. Finally, Q1 included necrotic cells, which are PI positive
and annexin V negative. b Western blots of Tax viral protein in ED, C8166, C91PL, and MT-4 cells exposed to NSC 19630 compared to DMSO-
treated controls. c HTLV-1-transformed cell lines (MT-4, C8166, C91PL, and 1186.94) and patient-derived cell lines (ED, TL, ATL-25, ATL-43T,
ATL-55T, LMY1, KK1, SO4, and KOB) were treated for 72 h with 3 μM of NSC 19630. Cells were stained with annexin V to measure the apoptotic
effect of the WRN helicase inhibitor. The percentage of apoptosis and necrosis was graphed. HTLV-1-transformed, ATL-derived IL-2-dependent cell
lines and IL-2-independent cell lines are represented in blue, yellow, and red, respectively. Tax viral protein is expressed in MT-4, C8166, C91PL,
1186.94, and ATL-25 cell lines [23]. Experiments were performed multiple times in duplicate. Representative results are shown in the final figures. d
Western blot of Caspase-3 and apoptotic markers Bcl-2 and Mcl-1 was performed in ED, ATL-55T, and LMY1 cells exposed to DMSO or 3 μM
of NSC 19630. Our analysis shows the activation of caspase-3 after treatment with the WRN helicase inhibitor. e Distraction of mitochondrial
transmembrane potential in ED cells treated with NSC 19630 compared to DMSO control. f Immunofluorescence of ɣ-H2AX and PCNA in ED cells
exposed for 72 h with 3 μM of NSC 19630 compared to DMSO control. Fluorescent images were captured by using the ×100 objective
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hypothesis, we tested NSC 19630’s apoptotic effect on a
Tax-expressing cell line (MT-4) versus a Tax-negative
cell line (ED). Evident induction of cell death was noted
in both Tax-positive and Tax-negative cells (Fig. 3a).
Then we investigated if the compound affects Tax ex-
pression in three Tax-positive cell lines (C8166, MT-4,
and C91PL); an ED-negative cell line was included in
our analysis. Tax expression was found to be unchanged
in NSC-treated cells compared to a DMSO control
(Fig. 3b), suggesting that Tax expression is not a marker
of drug sensitivity. A possible explanation of our finding
is that Tax inhibits Homologous Recombination repair
in an NF-κB-dependent manner [21]; however, constitu-
tive activation is described in ATL cells that do not ex-
press detectable Tax [50].
Our preliminary data show that a WRN helicase in-
hibitor induces apoptosis in vitro (Fig. 3a), so we decided
to include additional cell lines (MT-4, C8166, C91PL,
and 1186.94) and nine ATL patient-derived cell lines
(Fig. 3c). Previous studies suggest that IL-2-dependent
ATL cell lines represent a model of smoldering and


























































































































































Fig. 4 ATL-55T and LMY1 cell lines are sensitive to NSC 617145. a HTLV-1-transformed (MT-4, C8166, C91PL, 1186.94) and ATL-derived (ED, TL,
ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) cell lines and normal resting PBMCs were treated with increasing doses of NSC 617145 (0.02, 0.2,
2, and 20 μM). Inhibition of cellular growth was measured by using cell count. Experiment was performed multiple times in duplicate. Representative
results are shown in the final figures. b Patient-derived cell line, ATL-55T, was exposed to increasing amounts of NSC 617145 for 4 days, and
the anti-proliferative effect was evaluated by cell count and XTT assay. Representative results are shown in the final figures. P values were calculated
using paired two-sided Student’s t test. c LMY1-ATL-derived cells were treated with 0.25 μM of NSC 617145 for 96 h and stained with crystal violet.
Cell count and XTT assay were used to measure the cellular growth of NSC 617145-treated cells compared to DMSO control cells. Experiment was
performed multiple times in duplicate. Representative results are shown in the final figures. P values were calculated by using paired and two-tailed
Student’s t test and indicated in the figure. d ATL-55T and LMY1 cells were stained with annexin V to measure the apoptotic effect of the WRN
helicase inhibitor NSC 617145. Cells were treated for 92 h with 0.25 μM of NSC 617145. e The figures include the percentage of cells in the four
quarters: Q1, Q2, Q3, and Q4. Q3 included the live cells that are annexin V and PI negative. Q4 included early apoptotic cells, which are annexin V
positive and PI negative. Q2 included cells in late apoptosis, which are both annexin V and PI positive. Finally, Q1 included necrotic cells, which
are PI positive and annexin V negative. Experiment was performed multiple times in duplicate. Representative results are shown in the
final figures
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better relate to the acute form of ATL. To investigate the
potential use of WRN in various stages of ATL disease, we
selected ATL-IL-2-independent (ED, TL, and ATL-25)
and ATL-IL-2-dependent (ATL-43T, ATL-55T, LMY1,
KK1, SO4, and KOB) cell lines for study. These cells were
exposed for 72 h to the WRN helicase inhibitor and ana-
lyzed by annexin V/PI staining to measure the percentage
of apoptosis induced by the compound (Fig. 3c). Signifi-
cant levels of apoptosis were detected in IL-2-dependent
and IL-2-independent ATL cell lines (Fig. 3c). These re-
sults suggest that HTLV-1-transformed ATL cells are
highly sensitive to the WRN inhibitor NSC 19630 and that
patients with the chronic, smoldering, or acute form of
ATL are potential candidates for this therapeutic agent.
To gain some insights into the molecular mechanisms
involved in NSC 19630’s effects on ATL cells, we next
investigated disruption of the mitochondrial transmem-
brane potential (ΔΨm) (Fig. 3f ). Activation of mitochon-
drial pathway cell death leads to the opening of the
mitochondrial permeability transition (MPT) pore. The
major consequences of this event are the disruption of
ΔΨm and the release of pro-apoptotic proteins. Our
analyses show that treatment with the NSC 19630 in-
hibitor resulted in the collapse of mitochondrial trans-
membrane potential in ED cells (Fig. 3f ). Since the loss
of mitochondrial transmembrane potential is associated
with the activation of the caspase pathway [51], we in-
vestigated the activation of caspase-3, an essential
mediator of apoptosis activated by proteolytic cleavage.
Our data indicate that cleaved caspase-3 products were
readily detected in ED-treated cells when compared to
DMSO-treated control cells (Fig. 3d). We then analyzed
the expression of B-cell lymphoma 2 (Bcl-2) (Fig. 3d), a
protein that prevents apoptosis either by sequestering
caspases or by preventing the release of mitochondrial
apoptogenic factors, such as cytochrome c, and an
apoptosis-inducing factor, AIF, into the cytoplasm [52].
Consistent with results from annexin V/PI, the treat-
ment with the WRN helicase inhibitor led to decreased
Bcl-2 expression in ED-treated cells (Fig. 3d). Previous
studies showed that an increased expression of Mcl-1
significantly inhibits progression through the S-phase of
the cell cycle [53]. Consistent with our cell cycle results
demonstrating that exposure to the WRN helicase in-
hibitor results in S-phase arrest (Fig. 1a), increased levels
of Mcl-1 were detected in ED-treated cells (Fig. 3d).
Moreover, we performed Western blot of caspase-3, Bcl-
2, and Mcl-1 on protein lysates of ATL-55T and LMY1
treated with DMSO or NSC 19630. As expected, no sig-
nificant change of expression was noted (Fig. 3d), con-
firming that these lines are less sensitive to the drug.
The WRN helicase stabilizes and maintains the repli-
cation fork during DNA replication. Failure to stabilize
the fork induces DNA double-strand breaks (DDSB); in
fact, treatment with replication inhibitors induces fork
collapse, leading to serious DNA damage and cell death
[54]. Consistent with this concept, M. Aggarwal et al.
demonstrated that a WRN inhibitor, NSC 19630, induces
DDSB and accumulation of PCNA foci, which is associ-
ated with stalled replication forks [30]. In order to inves-
tigate if apoptosis is WRN-dependent in an HTLV-1
context, we dual-stained -H2AX (a specific marker of
DDSB) and PCNA in cells exposed to NSC 19630 com-
pared to DMSO-treated cells. Our analysis shows accu-
mulation of PCNA and -H2AX foci, suggesting that
the treatment induces DNA replication issues and, con-
sequentially, DNA damage (Fig. 3e).
NSC 19630-resistant ATL-55T and LMY1 cell lines are
sensitive to NSC 617145
Data presented above suggest that NSC 19630 is a
promising agent for the treatment of ATL. However, our
analyses show that the apoptotic effect of the WRN heli-
case inhibitor was very limited in two ATL lines, namely
LMY1 and ATL-55T (Fig.3c), suggesting potential resist-
ance mechanisms that warrant further investigations.
We studied the endogenous expression of WRN heli-
cases in HTLV-1-transformed and ATL-derived cell
lines. Consistent with previously published studies, our
analyses show no direct correlation between levels of
WRN protein expression and sensitivity to the WRN in-
hibitor (data not shown).
Table 1 Estimated IC50 of NSC 19630 in HTLV-1-transformed
and patient-derived cells
HTLV-1-transformed cell lines IC50 (μM)
MT-4 1.99 ± 0.065
C8166 2.84 ± 0.19
C91PL 2.76 ± 0.28
1186.94 2.23 ± 0.3
ATL-derived cell lines IC50 (μM)
ED 0.75 ± 0.053
TL 1.73 ± 0.29
ATL-25 1.79 ± 0.22
ATL-43T 1.69 ± 0.23
ATL-55T 6.1 ± 0.15
LMY1 4.35 ± 0.21
KK1 1.64 ± 0.038
SO4 1.45 ± 0.12
KOB 1.73 ± 0.086
We tested the HTLV-1-transformed, ATL-derived cell lines (MT-4, C8166, C91PL,
1186.94, ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) with increasing
doses of NSC 19630 (0.2, 2, and 20 μM), and inhibition of cellular growth was
measured by using cell count. We calculated the IC50 for every cell line by using
logarithmic transformation and the values are reported in the table. Our analysis
shows that ATL-55T and LMY1 were found to be less sensitive compared to the
HTLV-1- and ATL-derived cell lines included in the study
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We then investigated NSC 617145, a WRN inhibitor
identified as a close structural analog of NSC 19630 but
with more potent inhibition of WRN helicase activity.
We next exposed HTLV-1-transformed, ATL-derived
cell lines (MT-4, C8166, C91PL, 1186.94, ED, TL, ATL-
25, ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) and
resting PBMCs isolated from healthy donors to increas-
ing doses of NSC 617145 (0.02, 0.2, 2, and 20 μM), and
inhibition of cellular growth was measured by cell count
(Fig. 4a). We calculated the IC50 for every cell line by
using logarithmic transformation and the values are re-
ported in Table 2. Our analysis clearly shows that NSC
617145 was found to be more potent in inhibiting cellu-
lar growth compared to NSC 19630. In fact, ATL-55T
cells were sensitive when exposed to increasing concen-
trations of NSC 617145, which inhibited cellular growth,
as shown by cell count and XTT proliferation assay
(Fig. 4b, c). Next, we exposed LMY1 cells to 0.25 μM for
4 days then stained with crystal violet. Consistently,
again, a significant reduction in the number of cells was
observed in LMY1, which was confirmed by cell count
and XTT assay (Fig. 4d). Finally, we performed apoptosis
assay and found that low concentrations of NSC 617145
induced high levels of cell death in both ATL-55T and
LMY1 cell lines (Fig. 4e). Interestingly, limited inhibition
of proliferation was noted in normal PBMCs (Fig. 4a).
To confirm the limited effect of WRN inhibitor on normal
cells, we estimated the IC50 in an HTLV-1-transformed
cell line, C91PL, and in resting PBMCs based on induction
of apoptosis. C91PL and normal resting PBMCs were ex-
posed to increasing logarithmic doses (0.02, 0.2, and
2 μM) or DMSO vehicle as a control. Induction of cell
death was measured by using annexin V/PI staining (data
not show). Our analysis shows that the IC50 in normal
cells is higher compared to the HTLV-1-transformed cell
line C91PL (0.32 ± 0.013 and 0.13 ± 0.047, respectively),
suggesting that NSC 617145 might be suitable for treating
ATL patients.
Overall, our data suggest that HTLV-1-transformed
ATL cells are very sensitive to the anti-proliferative and
apoptotic effects of WRN helicase inhibitors.
Discussion
In the absence of effective chemotherapy treatments,
most patients with aggressive forms of the disease have a
poor clinical outcome. Patients with the lymphoma type
also have an unfavorable prognosis, with a median sur-
vival of 10.2 months, while patients with acute ATLL
present a median survival of 6.2 months [55]. The pro-
jected 4-year survival rates of patients with the acute
and lymphoma forms are only 1–5% [56]. DNA repair
inhibitors induced cell death in different human leuke-
mias [57, 58], and in the absence of an effective treat-
ment for ATLL, we decided to test the cytotoxicity of a
WRN helicase inhibitor. WRN helicases are involved in
HR DNA repair and helicase activity is required during
DNA replication. Previous studies showed that both
DNA repair and DNA replication are impaired in
HTLV-1-transformed cells.
In this study, we investigate small inhibitors of WRN
as a potential therapeutic agent for ATLL. NSC 19630
targets WRN helicase activity but does not affect other
DNA helicases (Bloom syndrome (BLM), Fanconi
anemia group J (FANCJ), RECQ1, RecQ, UvrD, or DnaB)
[30]. Our results demonstrate an apoptotic effect in-
duced by the WRN helicase inhibitor in HTLV-1-
transformed cells in vitro and in a majority of ATL-
derived cell lines tested. Inhibition of cellular prolifera-
tion and induction of apoptosis were demonstrated with
XTT proliferation assay, clonogenic assay, and annexin
V staining. Consistent with previous studies, we ob-
served an S-phase delay in ATL cells following treatment
with NSC 19630. All the cyclins tested (cyclins E, B1,
and D1) were found to be downregulated after the treat-
ment, except for cyclin A, which is specific to the S-phase
of the cell cycle. The effect of the WRN inhibitor was
found to be dose- and time-dependent. Exposure to 3 μM
of NSC 19630 shows significant caspase-dependent apop-
tosis in HTLV-1-transformed and patient-derived cells,
both IL-2-dependent and IL-2-independent. We found a
disruption of the mitochondrial potential, suggesting that
the WRN inhibitor induces cell death through an intrinsic
Table 2 Estimated IC50 of NSC 617145 in HTLV-1-transformed
and patient-derived cells
HTLV-1-transformed cell lines IC50 (μM)
MT-4 0.19 ± 0.042
C8166 0.22 ± 0.023
C91PL 0.21 ± 0.0091
1186.94 0.22 ± 0.063
ATL-derived cell lines IC50 (μM)
ED 0.15 ± 0.033
TL 0.17 ± 0.039
ATL-25 0.16 ± 0.007
ATL-43T 0.099 ± 0.013
ATL-55T 0.22 ± 0.0012
LMY-1 0.29 ± 0.0087
KK1 0.28 ± 0.032
SO4 0.14 ± 0.061
KOB 0.17 ± 0.031
We tested the HTLV-1-transformed, ATL-derived cell lines (MT-4, C8166, C91PL,
1186.94, ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) with increasing
doses of NSC 617145 (0.02, 0.2, and 2 μM), and cell count was used to measure
the inhibition of cellular growth. We calculated the IC50 for every cell line by
using logarithmic transformation and the values are reported in the table. Our
analysis clearly shows that NSC 617145 is more potent in inhibiting cellular prolif-
eration compared to NSC 19630
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apoptotic pathway. Consistently, expression of Bcl-2 in-
trinsic anti-apoptotic factor was reduced in ED cells ex-
posed to the WRN inhibitor. Our study shows that the
WRN inhibitor efficiently kills HTLV-1-transformed and
patient-derived cells. In addition, non-cancerous cells are
resistant to the anti-proliferative and apoptotic effects of
NSC 19630 [30], suggesting that NSC 19630 may repre-
sent a suitable strategy for initiation of phase I clinical tri-
als. Our study also identified two cell lines less sensitive to
NSC 19630, ATL-55T and LMY1. Nonetheless, these cells
were efficiently killed by an NSC 19630 analog, NSC
617145, with more potent inhibitory effects on WRN heli-
case activity. In addition, a possible explanation of the dif-
ferent sensitivities to WRN helicase inhibitors in different
ATL cells is that the compounds act on different domains
of the enzyme. NSC 19630 is reported to inhibit the heli-
case domain and mildly reduce the ATPase and exonucle-
ase activities of WRN. On the other hand, NSC 617145
reduces mainly the ATPase domain in a dose-dependent
manner [59].
Conclusions
The WRN inhibitors NSC 19630 and NSC 617145 effi-
ciently kill HTLV-1-transformed and patient-derived cells,
suggesting that WRN helicases represent a novel thera-
peutic target for ATLL patients.
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